Published

ANANDA Scientific Announces a Clinical Trial Evaluating Nantheia™ ATL5, in the treatment of Co-Occurring Opioid Use Disorder and Chronic Pain

Summary by Financial Post
GREENWOOD VILLAGE, Colo. & NEW HAVEN, Conn. -- ANANDA Scientific Inc., a research-focused biopharmaceutical company, today announced the commencement of a clinical trial evaluating Nantheia™ ATL5, an investigational drug using cannabidiol (CBD), leveraging ANANDA’s proprietary delivery technology, co-administered with delta-9-tetrahydrocannabinol (THC), for its potential efficacy in treating co-occurring opioid use disorder (OUD) and chronic …
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources lean Right
100% Right
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.